A Phase 1 interventional study of ONO-7913 and ONO-4538 in Metastatic Pancreatic Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Pancreatic Neoplasms with a site in Japan — 17 open to participants now, 34 under way, 8 of them phase 3. Pancreatic Neoplasms · Japan.
Among the 93 studies in Pancreatic Neoplasms with a site in Japan, this one is the 68th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2021, is one of 25 in phase 1, reaches primary completion later than 13 of the 33 other live ones, and was the 78th registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →17 of the 93 studies in Pancreatic Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan, United States, Belgium and 10 more countries
Ages 18+
Incyte Corporation · Sites in Japan, United States, Australia and 19 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in Japan, United States, Australia and 18 more countries
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in Japan, United States, Brazil and 8 more countries
Ages 18+
Cosomil, Inc. · Sites in Japan
Ages 20+ · Healthy volunteers
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 33 · Phase 3 14 · Phase 4 4
First in 2001; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 120 across the 84 interventional studies, 150 across the 7 observational. Of the 47 that completed or were terminated, 15 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 3 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Pancreatic Neoplasms with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06043921Invitae CorporationMulticenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel | 2026-12 |
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
Add all 11 to your calendar (.ics) → With an account.
Among the 93 studies in Pancreatic Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-7913 · Drug: ONO-4538 · Drug: Oxaliplatin · Drug: Levofolinate · Drug: Irinotecan · Drug: Fluorouracil
Specified dose on specified days
Also known as: Magrolimab
Specified dose on specified days
Also known as: Nivolumab
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Dose-limiting toxicities(DLT)
Time frame: 28 days
Adverse event(AE)
Time frame: UP to 30 days after the last dose
Pharmacokinetics(serum concentration of ONO-7913)
Time frame: Through study completion, an average of 6 months
Pharmacokinetics(serum concentration of ONO-4538)
Time frame: Through study completion, an average of 6 months
Overall response rate (ORR)
Time frame: Through study completion, an average of 6 months
Disease control rate (DCR)
Time frame: Through study completion, an average of 6 months
Overall survival (OS)
Time frame: Through study completion, an average of 6 months
Progression-free survival (PFS)
Time frame: Through study completion, an average of 6 months
Duration of response (DOR)
Time frame: Through study completion, an average of 6 months
Time to response (TTR)
Time frame: Through study completion, an average of 6 months
Best overall response (BOR)
Time frame: Through study completion, an average of 6 months
Percentage of change in the sum of tumor diameters of target lesions
Time frame: Through study completion, an average of 6 months
Maximum percentage of change in the sum of tumor diameters of target lesions
Time frame: Through study completion, an average of 6 months
Changes in tumor markers (CEA and CA19-9)
Time frame: Through study completion, an average of 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Jun 2027, 71 months after the start.
Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 71 months is above that.
Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Dec 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Magrolimab
Ono Pharmaceutical Co., Ltd. →